<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21513">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01666912</url>
  </required_header>
  <id_info>
    <org_study_id>PPI-12-0732</org_study_id>
    <nct_id>NCT01666912</nct_id>
  </id_info>
  <brief_title>Postpartum Etonogestrel Implant for Adolescents</brief_title>
  <acronym>PPImplant</acronym>
  <official_title>Etonogestrel-releasing Subdermal Implant for Adolescents in the Postpartum Period: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study comparing two groups of 48 adolescent women each.  The
      intervention group will receive a contraceptive implant postpartum, prior to discharge from
      the hospital. The control group will receive a contraceptive implant at the usual 6 week
      postpartum clinic visit.  During prenatal care, participants will be consented and screened
      for enrollment. After delivery, these women will be assessed and consented for enrollment
      into the study. Women who consent for enrollment will be randomized.  Women will be followed
      up at 3 months, 6 months, 9 months, and 1 year after contraceptive implant insertion. At
      each follow up, women will be assessed for continuation of and satisfaction with this method
      of contraception.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Continuation at 1 year</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the use of the contraceptive implant at one year postpartum among women who have the implant placed immediately postpartum vs. at 6 weeks postpartum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess satisfaction with the contraceptive implant inserted in the postpartum period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid repeat pregnancy</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess rapid repeat pregnancies among the study population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Adolescence</condition>
  <condition>Contraception</condition>
  <condition>Postpartum</condition>
  <arm_group>
    <arm_group_label>6 week postpartum contraceptive implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized to receive contraceptive implant at normal 6 week postpartum visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate postpartum contraceptive implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomized to receive contraceptive implant prior to leaving the hospital postpartum</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Contraceptive implant</intervention_name>
    <arm_group_label>6 week postpartum contraceptive implant</arm_group_label>
    <arm_group_label>Immediate postpartum contraceptive implant</arm_group_label>
    <other_name>Implanon, Nexplanon, etonogestrel contraceptive implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents ages 14-24 attending prenatal care

          -  Greater than 20 weeks estimated gestational age

          -  English or Spanish-speaking

          -  Desire to use the contraceptive implant for contraception postpartum

          -  Anticipated delivery of a healthy infant vaginally or by cesarean.

        Exclusion Criteria:

        Participants will not be eligible for participation if they have any contraindications to
        contraceptive implant use, including

          -  current or past history of thrombosis or thromboembolic disorders

          -  hepatic tumors (benign or malignant)

          -  active liver disease

          -  undiagnosed abnormal genital bleeding

          -  known or suspected carcinoma of the breast (or a personal history of breast cancer)

          -  hypersensitivity to any of the components of the contraceptive implant.

          -  Current use of any medications known to induce hepatic enzymes, including but not
             limited to: barbiturates, bosentan, carbamazepine, felbamate, griseofulvin,
             oxcarbazepine, phenytoin, rifampin, St. John's wort, or topiramate

        Characteristics that would preclude involvement after delivery:

          -  Birth of a stillborn infant.

          -  Maternal ICU admission after delivery

          -  Maternal postpartum hemorrhage requiring blood transfusion

          -  Prolonged hospital stay (&gt;7 days) postpartum

          -  Coagulopathy associated with the pregnancy

          -  Severe pregnancy-induced hypertension

          -  Fever &gt;38 degrees C postpartum

          -  Adolescent women who are not competent to consent, secondary to stress from the labor
             process, for example severe pain or sleep deprivation, will not be offered enrolment
             into the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy G Bryant, MD, MSCR</last_name>
    <phone>919-843-6473</phone>
    <email>amy_bryant@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gretchen S Stuart, MD, MPHTM</last_name>
    <phone>919-966-7783</phone>
    <email>gstuart@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy G Bryant, MD, MSCR</last_name>
      <phone>919-843-6473</phone>
      <email>amy_bryant@med.unc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 9, 2013</lastchanged_date>
  <firstreceived_date>August 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Amy Bryant</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>adolescence</keyword>
  <keyword>contraception</keyword>
  <keyword>postpartum</keyword>
  <keyword>rapid repeat pregnancy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>3-keto-desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
